A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

NCT02449018 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease, COPD

Interventions

DRUG: QBW251
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals